🇺🇸 FDA
Patent

US 11827691

Serpin fusion polypeptides and methods of use thereof

granted A61KA61K38/00A61P

Quick answer

US patent 11827691 (Serpin fusion polypeptides and methods of use thereof) held by Inhibrx, Inc. expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx, Inc.
Grant date
Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00, A61P, A61P1/00, A61P1/04